

Awards

Prostate Cancer Research Award of the European Association of Urology 2015, **M.Spahn**

Second prize of the XXXVI edition Perez Castro awards of ARCHIVOS ESPAÑOLES DE UROLOGIA, for the paper "Current role for surgery for high risk prostate cancer" published in Arch. Esp.Urol 2013. Joniau S, Van der Eeckt K, Briganti A, Gontero P, Van Bruwaene S, Jeffrey Karnes R, **Spahn M**, Van Poppel Hr European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). Arch Esp Urol. 2013 Apr;66(3):259K73, 259K74. English, Spanish.

Best Poster Award, Prostate Cancer Session, Markers II. Annual Meeting of the American Association of Urology, Atlanta, May 19-23, 2012. Validation of the new biomarker microRNA221 to predict cancer related death in high risk prostate carcinoma: results of a meta-analysis. **Spahn, M.**, Juergen, C., Stroebel, P., Lerut, E., van Poppel, H., Riedmiller, H., Joniau, S., Kneitz, B.

Best Poster Award, Prostate Cancer Session: High risk disease. 27th Congress of the European Association of Urology, Paris, February 24-28, 2012. Outcome of multimodality treatment of cT4 very high risk prostate cancer with radical prostatectomy as initial step: A multi-institutional outcome study of 62 patients. **Spahn, M.**, Joniau, S., Abdollah, F., Tutolo, M., Di Trapani, E., Gontero, P., Kneitz, B., Bader, P., Frohneberg, D., Van Poppel, H., Karnes, R.J.

International Urological Oncology Award, European Association of Urology 2011. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. **Spahn M.** and Joniau S.

1. Vortragspreis der Deutschen Gesellschaft für Urologie, Hamburg 2011. MicroRNA221 is a strong and independent predictor of clinical progression and CSS in high risk prostate cancer. **Spahn M.**, S. Joniau, S. Kneitz, C.K.J. Scholz, C. Kalogirou, E. Lerut, P. Ströbel, M. Schubert, H. van Poppel, H. Riedmiller, B. Kneitz.

Best Poster Award, Prostate Cancer Session: Prostate Cancer localised. Annual Meeting of the American Association of Urology, Washington, May 14-19, 2011. MicroRNA221 is a strong and independent predictor of clinical progression and CSS in high risk prostate cancer. J Urol 2011, Vol. 185, Issue 4, Supplement, e653K654 **Spahn, M.**, Joniau, S., Kneitz, S., Scholz, C.K.J., Kalogirou, C., Lerut, E., Ströbel, P., Schubert, M., Van Poppel, H., Riedmiller H. and Kneitz, B.

Best Poster Award, Prostate Cancer Session, 26th Congress of the European Association of Urology, 2011, Vienna, March 18-22. Downregulation of miR221 is a strong and independent predictor of clinical progression and CSS in high risk prostate cancer. **Spahn, M.**, Joniau, S., Kneitz, S., Scholz, C.J., Schubert, M., Kalogirou, C., Lerut, E., Stroebel, P., Van Poppel, H., Riedmiller, H., Kneitz, B.

European Organisation for Research and Treatment of Cancer (EORTC) EORTC tutorial grant on the participation of the ASCO/EORTC course on diagnostic development 2010

Best Poster Award Session 18, Experimental Oncology, 61. Kongress der Deutschen Gesellschaft für Urologie, Dresden, 16–19 September 2009. Downregulation of microRNA221 hallmarks prostate cancer metastasis and is a predictor of clinical recurrence. **Spahn M**, Kneitz S, Scholz CJ, Stenger N, Rudiger T, Strobel P, Riedmiller H, Kneitz B.

Best Poster Award, Prostate Cancer Session, Genetic and epigenetic changes in PCa, 24th Congress of the European Association of Urology Stockholm, March 17-21, 2009. Comparison of miRNA profiles in high and intermediate risk prostate carcinoma: role of miR16 in development and progression of prostate carcinoma. European Urology Supplements 2009;8:316K316. Kneitz B, Kneitz S, Stenger N, Strobel P, Riedmiller H, **Spahn M**

1. Vortragspreis der Deutschen Gesellschaft für Urologie, Stuttgart, 2008. Kontinente Harnableitung und Nierentransplantation: Langzeitergebnisse. Kocot A., **Spahn M.**, Ardelt P., Löser A., Vergho D., Lopau K., Gerharz E., Riedmiller H.